Table 3.
The attribution risk of obesity for the prevalence of adipose tissue insulin resistance
| It (%) | Io (n0/N0) | Ie (ne/Ne) | ARP (%) | PARP (%) | |
| Total | |||||
| General obesity (BMI≥25 kg/m2) | 33.3 | 95/393 | 71/106 | 63.9 | 27.3 |
| Abdominal obesity (WC≥90 cm for male and WC≥80 cm for female) | 33.3 | 43/243 | 123/256 | 63.1 | 46.8 |
| Male | |||||
| General obesity (BMI≥25 kg/m2) | 33.3 | 49/190 | 28/42 | 61.3 | 22.5 |
| Abdominal obesity (WC≥90 cm) | 33.3 | 33/158 | 44/74 | 64.9 | 37.2 |
| Cut-off point in this study (WC≥83.5 cm) | 33.3 | 7/91 | 70/141 | 84.5 | 76.9 |
| Female | |||||
| General obesity (BMI≥25 kg/m2) | 33.3 | 46/203 | 43/64 | 66.2 | 31.8 |
| Abdominal obesity (WC≥80 cm) | 33.3 | 10/85 | 79/182 | 72.8 | 64.5 |
| Cut-off point in this study (BMI≥21.77 kg/m2) | 33.3 | 7/98 | 82/169 | 85.4 | 78.7 |
ARP, attributable risk per cent; BMI, body mass index; Ie, prevalence of adipose tissue insulin resistance for the obese group included in obesity defined by BMI≥25 kg/m2 (whole body obesity), WC≥80 cm for female/90 cm for male (abdominal obesity) or cut-off value in this study (WC≥83.5 cm for male and BMI≥21.77 kg/m2 for female); Io, prevalence of adipose tissue insulin resistance for non-obese population; It, prevalence of adipose tissue insulin resistance for the study population; PARP, population attributable risk per cent; WC, waist circumference.